Clearbridge Investments LLC Sells 43,345 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Clearbridge Investments LLC trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,686,384 shares of the biopharmaceutical company’s stock after selling 43,345 shares during the quarter. Clearbridge Investments LLC owned 1.59% of Intra-Cellular Therapies worth $140,847,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $32,000. GAMMA Investing LLC raised its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth about $96,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $97,000. Finally, Quarry LP increased its position in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 1,300 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.81 on Monday. The firm has a market cap of $14.04 billion, a P/E ratio of -151.50 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.87. The company has a 50 day simple moving average of $129.12 and a two-hundred day simple moving average of $99.80.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ITCI. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their target price for the company from $119.00 to $132.00 in a report on Friday, January 31st. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, StockNews.com started coverage on Intra-Cellular Therapies in a report on Friday. They set a “hold” rating for the company. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.